In 2025, Eli Lilly's leading three products, Mounjaro, Zepbound, and Verzenio, made up close to of the company's sales. GLP-1 drugs primarily drove the increase in sales share.Â
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how ÌÇÐÄÆÆ½â°æ can support your business.
Eli Lilly and Company, & U.S. Securities and Exchange Commission. (February 12, 2026). Sales share of Eli Lilly's three major drugs worldwide from 2021 to 2025 [Graph]. In ÌÇÐÄÆÆ½â°æ. Retrieved July 26, 2026, from /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/
Eli Lilly and Company, und U.S. Securities and Exchange Commission. "Sales share of Eli Lilly's three major drugs worldwide from 2021 to 2025." Chart. February 12, 2026. ÌÇÐÄÆÆ½â°æ. Accessed July 26, 2026. /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/
Eli Lilly and Company, U.S. Securities and Exchange Commission. (2026). Sales share of Eli Lilly's three major drugs worldwide from 2021 to 2025. ÌÇÐÄÆÆ½â°æ. ÌÇÐÄÆÆ½â°æ Inc.. Accessed: July 26, 2026. /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/
Eli Lilly and Company, and U.S. Securities and Exchange Commission. "Sales Share of Eli Lilly's Three Major Drugs Worldwide from 2021 to 2025." ÌÇÐÄÆÆ½â°æ, ÌÇÐÄÆÆ½â°æ Inc., 12 Feb 2026, /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/
Eli Lilly and Company & U.S. Securities and Exchange Commission, Sales share of Eli Lilly's three major drugs worldwide from 2021 to 2025 ÌÇÐÄÆÆ½â°æ, /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/ (last visited July 26, 2026)
Sales share of Eli Lilly's three major drugs worldwide from 2021 to 2025 [Graph], Eli Lilly and Company, & U.S. Securities and Exchange Commission, February 12, 2026. [Online]. Available: /statistics/1660133/eli-lilly-s-three-major-drug-sales-share/